You are here

Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

Last updated on September 10, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult subjects with moderately to severely active rheumatoid arthritis who start
treatment with tofacitinib in usual clinical practice conditions in compliance with
the label

1. Patients aged ≥ 18 years

2. Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist

3. Patients with moderate to severe RA diagnosed according to local practice who
have been started on treatment with tofacitinib.

4. Patients eligible for tofacitinib treatment according to current approved Summary
of Product Characteristics (SmPC).

5. Evidence of a personally signed and dated informed consent document indicating
that the patient (or a legally acceptable representative) has been informed of
all pertinent aspects of the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients meeting any of the following criteria will not be included in the study:

1. Exclusion Criteria according to the Xeljanz® SmPC.

2. Contraindications to Xeljanz® according to SmPC.

3. Hypersensitivity to the active substance (tofacitinib) or to any of the
excipients.

4. Active tuberculosis (TB), serious infections, such as sepsis, or opportunistic
infections.

5. Receipt of any investigational drug within 3 months before study inclusion as
well as currently not participating in an interventional clinical trial.

6. Subjects who have received any previous treatment with tofacitinib or other JAK
inhibitors.

7. Subjects who are investigational site staff members or subjects who are Pfizer
employees directly involved in the conduct of the trial.

NCT04079920
Pfizer
Not yet recruiting
Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now